Recent News

  1. Jubilant DraxImage had significant presence at this year’s Mid-Winter meeting featuring important information on  V/Q imaging (MAA), Radioiodine therapy (HICON) and most importantly introducing its newest product approved by the USFDA; RubyFill.
  2. Jubilant Pharma, a solutions provider to global pharmaceutical customers, announced today it has appointed Michael Rossi as President of Jubilant DraxImage. Jubilant Pharma announced today it has appointed Michael Rossi as President of Jubilant DraxImage effective immediately. Michael will be responsible for leading the Jubilant DraxImage business, a subsidiary of (...)
  3. RUBY-FILL® is an approved cutting edge technology for PET myocardial perfusion imaging (MPI) under rest and pharmacological stress conditions to evaluate regional myocardial perfusion in adult patients with suspected or existing coronary artery disease. MONTREAL, Quebec – October 3, 2016 Jubilant DraxImage Inc., (“DraxImage”) a wholly Owned Subsidiary of Jubilant (...)
  4. JDI clarifies: no impact on supply from Chalk River shutdown JDI has received  enquiries from its customers with regards to our supply of I-131 following the announcement of the closure of the Chalk River reactor. JDI wishes to inform its customers purchasing JDI I-131 that JDI does not anticipate any (...)
  5. Jubilant DraxImage and Cyclopharm Terminate Technegas Licensing Agreement Negotiations MONTREAL, Quebec – May 12, 2016 –  Jubilant DraxImage (“DraxImage”) announced today that despite several months of negotiations, it and Cyclopharm (ASX: CYC) (“CYC”) have terminated their negotiations of an exclusive license agreement for the development and marketing of CYC’s lung (...)
  6. Jubilant DraxImage launches “Not all Iodine-131 is created equal” Campaign Jubilant DraxImage is pleased to announce the launch of its “Not all Iodine-131 is created equal” campaign. We wish to raise awareness about the differences between FDA approved pharmaceutical-grade I-131 drug products such as Jubilant DraxImage’s HICON® I-131 and radiochemical-grade (...)
  7. Jubilant DraxImage launches Count On It DRAXIMAGE® MAA 350K Particles Campaign Jubilant DraxImage is pleased to announce the launch of its Count On It DRAXIMAGE® MAA 350K Particles Campaign. The campaign speaks primarily to radiopharmacists and Nuclear Medicine technologists that prepare unit doses of DRAXIMAGE® MAA for use in patients (...)
  8. JDI releases a patient video to demystify the role of Radioactive Iodine in the treatment of Differentiated Thyroid Cancer (DTC) Jubilant DraxImage is pleased to announce the launch of its first video series focused on one of the fastest growing cancers in North America: thyroid cancer. The production of this (...)
  9. JDI releases a patient video to demystify the role of Radioactive Iodine in the treatment of Differentiated Thyroid Cancer (DTC) Jubilant DraxImage is pleased to announce the launch of its first video series focused on one of the fastest growing cancers in North America: thyroid cancer. The production of this (...)
  10. MONTRÉAL et SYDNEY–Jubilant DraxImage Inc. (« DraxImage ») et Cyclopharm Limited (« CYC ») sont heureuses d’annoncer la signature d’une liste de conditions, sous réserve d’une diligence raisonnable satisfaisante et de l’exécution de l’Accord définitif MONTRÉAL et SYDNEY – Jubilant DraxImage Inc. (« DraxImage ») et Cyclopharm Limited (« CYC (...)